Evidence map›Paper›PMID 40563422›Full record

ArticleBiomolecules2025

Identification of Splicing Regulatory Activity of ATXN1 and Its Associated Domains.

Ai Ohki, Masahide Kato, Yoshitaka Aoki, Arisa Kubokawa, Motoaki Yanaizu, Yoshihiro Kino

Abstract read
In one paragraph

Article in Biomolecules, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Ai OhkiDepartment of RNA Pathobiology and Therapeutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi 204-8588, Tokyo, Japan.
Masahide KatoDepartment of RNA Pathobiology and Therapeutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi 204-8588, Tokyo, Japan.
Yoshitaka AokiDepartment of RNA Pathobiology and Therapeutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi 204-8588, Tokyo, Japan.
Arisa KubokawaDepartment of RNA Pathobiology and Therapeutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi 204-8588, Tokyo, Japan.
Motoaki YanaizuDepartment of RNA Pathobiology and Therapeutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi 204-8588, Tokyo, Japan.
Yoshihiro KinoDepartment of RNA Pathobiology and Therapeutics, Meiji Pharmaceutical University, 2-522-1, Noshio, Kiyose-shi 204-8588, Tokyo, Japan.ORCID 0000-0003-0862-8065

Funding

Ministry of Education, Culture, Sports, Science and Technology 16K07043Ministry of Education, Culture, Sports, Science and Technology 16K09683Ministry of Education, Culture, Sports, Science and Technology 19J15024Ministry of Education, Culture, Sports, Science and Technology 21K20700Ministry of Education, Culture, Sports, Science and Technology 22K07525
6 · The paper itself

Abstract

The expansion of the polyglutamine tract in ATXN1 contributes to the pathogenesis of SCA1. ATXN1 functions as a transcriptional regulator that interacts with multiple transcription factors, and transcriptional dysregulation has been observed in SCA1. In addition, splicing dysregulation has been identified in cells derived from SCA1 patients and model mouse tissues. Although ATXN1 binds to RNA and splicing factors, its direct involvement in pre-mRNA splicing remains unclear. Here, we demonstrate that ATXN1 regulates the alternative splicing of several minigenes. Using an

Indexed as

Alternative SplicingAtaxin-1AnimalsHEK293 CellsHumansMicePeptidesProtein DomainsRNA-Binding ProteinsRNA SplicingAtaxin-1ATXN1 protein, humanPeptidesRNA-Binding Proteinsalternative splicingATXN1RNA bindingspinocerebellar ataxia type 1

Identifiers

PMID40563422
PMCPMC12191242

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.